The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft ‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Condition: Graft Versus Host Disease Interventions: Biological: Alpha-1 antitrypsin (AAT); Biological: Placebo Sponsor: CSL Behring Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alpha-1 Antitrypsin Deficiency | Transplants